American Tech Today
SEE OTHER BRANDS

Hottest science and technology news from the United States

American Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.

Press releases published on May 7, 2025

Veeco Announces Over $35 Million in Advanced Packaging Lithography System Orders From IDM & OSAT Customers

Veeco Announces Over $35 Million in Advanced Packaging Lithography System Orders From IDM & OSAT Customers

PLAINVIEW, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced its received over $35 million of orders for its AP300™ Lithography systems in recent quarters from a wide-range of IDM and OSAT customers. The orders …

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte …

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context …

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, …

LiveRamp to Discuss Fiscal 2025 Fourth Quarter and Full Year Results

LiveRamp to Discuss Fiscal 2025 Fourth Quarter and Full Year Results

SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), a leading data collaboration platform, today announced that its fiscal 2025 fourth quarter and full year earnings release will be issued on Wednesday, May 21, 2025 after the financial …

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

-  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid …

red violet Announces First Quarter 2025 Financial Results

red violet Announces First Quarter 2025 Financial Results

BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended March 31, 2025. “We are extremely pleased to report another …

Astera Labs to Participate in the J.P. Morgan 53rd Annual Global Technology, Media, and Communications Conference

Astera Labs to Participate in the J.P. Morgan 53rd Annual Global Technology, Media, and Communications Conference

SANTA CLARA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Astera Labs (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced that it will participate in the J.P. Morgan 53rd Annual Global …

Crane NXT Reports First Quarter 2025 Results

Crane NXT Reports First Quarter 2025 Results

Completes Acquisition of De La Rue Authentication, a Global Leader in Security and Authentication Technologies Increases Sales Growth Guidance to 6% to 8% for Full Year 2025; Maintaining Full Year EPS Guidance of $4.00 to $4.30 WALTHAM, Mass., May 07, 2025 …

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

HeartCore to Present at Sidoti Micro-Cap Virtual Conference on May 21, 2025 at 11:30 a.m. ET

HeartCore to Present at Sidoti Micro-Cap Virtual Conference on May 21, 2025 at 11:30 a.m. ET

NEW YORK and TOKYO, May 07, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, will be virtually presenting and holding one- …

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net …

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment …

Veeco Reports First Quarter 2025 Financial Results

Veeco Reports First Quarter 2025 Financial Results

First Quarter 2025 Highlights: Revenue of $167.3 million, compared with $174.5 million in the same period last year GAAP net income of $11.9 million, or $0.20 per diluted share, compared with $21.9 million, or $0.37 per diluted share in the same period …

Century Aluminum Company Reports First Quarter 2025 Results

Century Aluminum Company Reports First Quarter 2025 Results

CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its first quarter 2025 results. First Quarter 2025 Financial Results $MM (except shipments and per share data)   Q1 2025   Q4 2024   Aluminum shipments ( …

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

—  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million —  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million —  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, …

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights …

Magnite Reports First Quarter 2025 Results

Magnite Reports First Quarter 2025 Results

Contribution ex-TAC(1) Grows 12% Year-Over-Year Contribution ex-TAC(1) from CTV Grows 15% Year-Over-Year Adjusted EBITDA(1) Grows 47% Year-Over-Year NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side …

electroCore Announces First Quarter 2025 Financial Results

electroCore Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service